Peptech's principal activities include undertaking research, development, production, formulation and marketing of peptides, and related products for the the pharmaceutical, veterinary and agricultural industries.
Peptech has recently posted a half-year net profit of $5.5 million, a strong cash position of $41.9 million and a 33.6% majority interest in leading UK drug development company, Domantis Limited.
The stock has been in a decline of recent times yet there seems to be a positive outlook and signs of buyer support are showing
Find out more by logging in to the members area at
www.theinsidetrader.com.au
>>>>>>>>>>
I don't hold.
PTD Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.